[HTML][HTML] Incretins as a potential treatment option for gestational diabetes mellitus
A Pilszyk, M Niebrzydowska, Z Pilszyk… - International Journal of …, 2022 - mdpi.com
Gestational diabetes mellitus (GDM) is a metabolic disease affecting an increasing number
of pregnant women around the world. It is not only associated with numerous perinatal …
of pregnant women around the world. It is not only associated with numerous perinatal …
[HTML][HTML] The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations
Cognitive impairment in individuals with diabetes represents a multifaceted and increasingly
prevalent health concern. This review critically examines the current evidence regarding the …
prevalent health concern. This review critically examines the current evidence regarding the …
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
B Gong, Z Yao, C Zhou, W Wang, L Sun… - European Journal of …, 2024 - Elsevier
Abstract Glucagon-like peptide-1 (GLP-1), secreted by L cells in the small intestine, assumes
a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on …
a central role in managing type 2 diabetes mellitus (T2DM) and obesity. Its influence on …
A Systematic Review of Semaglutide's Influence on Cognitive Function in Preclinical Animal Models and Cell-Line Studies
RO Tipa, DG Balan, MT Georgescu, LA Ignat… - International Journal of …, 2024 - mdpi.com
Since we aim to test new options to find medication for cognitive disorders, we have begun
to assess the effect of semaglutide and to conduct a review gathering studies that have …
to assess the effect of semaglutide and to conduct a review gathering studies that have …
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
DA Milder, TY Milder, SS Liang, PCA Kam - Anaesthesia, 2024 - Wiley Online Library
Background Glucagon‐like peptide‐1 receptor agonists are used increasingly in the
management of patients living with type 2 diabetes mellitus and obesity. In patients using …
management of patients living with type 2 diabetes mellitus and obesity. In patients using …
[HTML][HTML] Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el …
A Cases - nefrologia, 2023 - Elsevier
La enfermedad renal diabética, frecuente en pacientes con diabetes mellitus tipo 2, se
asocia con un marcado incremento de la morbimortalidad, especialmente cardiovascular, y …
asocia con un marcado incremento de la morbimortalidad, especialmente cardiovascular, y …
[HTML][HTML] The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep
EM Simpson, IJ Clarke, CJ Scott… - Journal of …, 2023 - joe.bioscientifica.com
Our previous studies showed that microinjection into the median eminence of the sheep of
glucagon-like peptide-1 (GLP-1) or its receptor agonist exendin-4 stimulates luteinising …
glucagon-like peptide-1 (GLP-1) or its receptor agonist exendin-4 stimulates luteinising …
Efficacy and safety of dapagliflozin versus liraglutide in patients with overweight or obesity and type 2 diabetes mellitus: a randomised controlled clinical trial in Tianjin …
H Zhaohu, H Xiao, S Hailin… - Journal of Diabetes …, 2022 - Wiley Online Library
Objective. We aimed to clarify the efficacy of dapagliflozin versus liraglutide in patients with
overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the …
overweight or obesity and type 2 diabetes mellitus (T2DM) at the beginning of the …
Perioperative management of patients on glucagon-like peptide-1 receptor agonists
GB Mizubuti, AMH Ho, LM da Silva… - Current Opinion in …, 2024 - journals.lww.com
While rapidly emerging evidence suggests that perioperative GLP-1-RAs use is associated
with delayed gastric emptying and increased risk of bronchoaspiration (particularly in …
with delayed gastric emptying and increased risk of bronchoaspiration (particularly in …
Cinchonine, a potential oral small-molecule glucagon-like peptide-1 receptor agonist, lowers blood glucose and ameliorates non-alcoholic steatohepatitis
H Xue, HJ Xing, B Wang, C Fu, YS Zhang… - Drug Design …, 2023 - Taylor & Francis
Purpose The glucagon-like peptide-1 receptor (GLP-1R) is an effective therapeutic target for
type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has …
type 2 diabetes mellitus (T2DM) and non-alcoholic steatohepatitis (NASH). Research has …